Immuno-Oncology Diagnostics - The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics. With Executive and Consultant Guides and including Customized Forecasting and Analysis 2020 to 2024

Immuno-Oncology Diagnostics - The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics. With Executive and Consultant Guides and including Customized Forecasting and Analysis 2020 to 2024

Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.

A revolution in cancer therapy is underway. New therapy based on using the body’s natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.


1. Introduction and Market Definition
1.1 What are Immuno-Oncology Diagnostics?
1.2 Immuno-oncology – the looming cure
1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
1.3 Market Definition
1.3.1 Market Size
1.3.2 Currency
1.3.3 Years
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and laboratory Testing - Perspective
1.4.1 U.S. Medicare Expenditures for Laboratory Testing
2. Immunotherapy – Guide to Immune Technologies
2.0 The Immune System
2.0.1 Innate immune system
2.0.1.1 Surface barriers
Immuno-Oncology Diagnostics 2020 to 2024 Page | 5
2.0.1.2 Inflammation
2.0.1.3 Complement system
2.0.1.4 Cellular barriers
2.0.1.5 Natural killer cells
2.0.2 Adaptive immune system
2.0.2.1 Lymphocytes
2.0.2.2 Killer T cells
2.0.2.3 Helper T cells
2.0.2.4 Gamma delta T cells
2.0.2.5 B lymphocytes and antibodies
2.0.3 Tumor immunology – the immune surveillance system
2.1 Immuno OncologyDiagnostics
2.1.1 Checkpoint Assays
2.1.1.1 Outlook for Checkpoint Assays
2.1.2 Cytokine Assays
2.1.2.1 Outlook for Cytokine Assays
2.1.3 Genomic Germline
2.1.3.1 Outlook for Genomic Germline
2.1.4 Genomic Tumour
2.1.4.1 Outlook for Genomic Tumour
2.1.5 Tumor Microenviroment
2.1.5.1 Outlook for Tumor Micro Environment
2.1.6 Others
2.1.6.1 Outlook for Other Diagnostics
3. Industry Overview
Immuno-Oncology Diagnostics 2020 to 2024 Page | 6
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Genomic Instrumentation Supplier
3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
3.1.4 Pharmaceutical/Reagent Supplier
3.1.5 Independent Testing Lab
3.1.6 Public National/regional lab
3.1.7 Hospital lab
3.1.8 Physician Lab
3.1.9 Audit Body
3.1.10 Certification Body
4. Market Trends
4.1 Factors Driving Growth
4.1.1 Outcome potential
4.1.2 Companion Diagnostics
4.1.3 Funding
4.1.4 Technology Environment
4.1.5 Target Solutions
4.2 Factors Limiting Growth
4.2.1 Complex Role of Diagnostics
4.2.2 Clinical Trials Role
4.2.3 Protocols
4.3 Diagnostic Technology Development
4.3.1 Combinations - Issues and Complexity
Immuno-Oncology Diagnostics 2020 to 2024 Page | 7
4.3.2 Shifting Role of Diagnostics
4.3.3 Multiplexing and Foundation One
4.3.4 The Disruption Dynamic
4.3.5 The Race for Biomarkers
4.3.6 The Next Five Years
5. Cancer Immunotherapy Recent Developments
5.1 Recent Developments – Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
Generex to Merge with NuGenerex Immuno-Oncology
Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop
Companion Diagnostics for Cancer Therapies
Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative
Breast Cancer
Icon Acquires MolecularMD
Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
Tumor Mutational Burden as Predictor of Immunotherapy Success
Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda
Abcam Acquires Calico Biolabs
Cancer Genetics and NovellusDx to Merge
ApoCell Expands Immuno-Oncology Biomarker Services
MRM Proteomics Inc and Exactis Innovation Partner
Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma
Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution
Immuno-Oncology Diagnostics 2020 to 2024 Page | 8
MolecularMD Launches Validated Tumor Mutation Burden Assay
Minomic Secures Key Patent in the United States and China
Biocartis and Wondfo Announce Joint Venture
Five Prime Therapeutics Announces Collaboration with Roche to Develop
Companion Diagnostics
Cancer Genetics Expands Immuno-Oncology Panel
10x Genomics Acquires Epinomics, To Launch ATAC-Seq Product
Qiagen, Freenome Partner to Improve Companion Diagnostic Development
Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime .115
Thermo Fisher Expands Oncomine Immuno-Oncology Assay Portfolio
Bristol-Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology
Immunotherapies
HalioDx announces high capacity IHC multiplex technology
MolecularMD to Implement Promega’s Technology
NCI, NanoString Collaborate to Evaluate Utility of PanCancer Gene Expression Panel
MIODx to Develop Immune Repertoire Sequencing Assay to Predict Immunotherapy
Response
Personal Genome Diagnostics Licenses Tumor Mutation Burden from MSKCC
HalioDx Closes €18.5M Series B Round
Announcement of the 2018 Nobel Prize in Physiology or Medicine
6. Profiles of Key Immunotherapy Companies
10X Genomics
Abbott Laboratories
Abcam
Adaptive Biotechnologies
Immuno-Oncology Diagnostics 2020 to 2024 Page | 9
Aethlon Medical
Agena Bioscience
Angle plc
Apocell
ARUP Laboratories
Beckman Coulter
Becton Dickinson
Bioarray Genetics
BioCartis
Biocept
Biodesix Inc
BioFluidica
BioGenex
bioMérieux
Bio-Rad
Bio-Techne
Bristol-Myers Squibb
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Charles River Laboratories
Chronix Biomedical
Circulogene
Clearbridge BioMedics
Clinical Genomics
Immuno-Oncology Diagnostics 2020 to 2024 Page | 10
Cynvenio
Cytolumina Technologies Corp.
CytoTrack
Dako (Agilent)
Diagnologix LLC
Epic Sciences
Exosome Diagnostics
Fluidigm Corp
Fluxion Biosciences
Foundation Medicine
Freenome
Genomic Health
GenomOncology
GRAIL
Guardant Health
HalioDx
Horizon Discovery
HTG Molecular Diagnostics
iCellate
Illumina
Incell Dx
Inivata
Integrated Diagnostics
Invivoscribe
Leica Biosystems
Immuno-Oncology Diagnostics 2020 to 2024 Page | 11
Luminex
MDx Health
Merck & Co., Inc
MIODx
Molecular MD
MRM Proteomics Inc
Myriad Genetics/Myriad RBM
Nanostring
Natera
Neogenomics
New Oncology
Oncocyte
Ortho Clinical Diagnostics
Perkin Elmer
Personal Genome Diagnostics
Pfizer
Promega
Protagen Diagnostics
Qiagen
Quanterix
Rarecells SAS
Roche Diagnostics
Siemens
Silicon Biosystems
SkylineDx
Immuno-Oncology Diagnostics 2020 to 2024 Page | 12
SRI International
Sysmex
Thermo Fisher
Trovagene
Vortex Biosciences
7. Global Market Size
7.1 Immuno-oncology Diagnostics Global Market Size by Country with Charts
7.2 Immuno-oncology Diagnostics Global Market Size by Type with Charts
8. Global Market by Type
8.1 Checkpoint Assay Market
8.1.1 Checkpoint Assay Market by Country with Chart
8.2 Cytokine Assay Market
8.2.1 Cytokine Assay Market by Country with Chart
8.3 Genome Germline Market
8.3.1 Genome Germline Market by Country with Chart
8.4 Genome Tumour Market
8.4.1 Genome Tumour Market by Country with Chart
8.5 Tumour Micro Environment Market
8.5.1 Tumour Micro Environment Market by Country with Chart
8.6 Other Market
8.6.1 Other Market by Country with Chart
9. Appendices
9.1 FDA Cancer Drug Approvals by Year
9.2 Clinical Trials Started 2010 to 2016
9.3 Prevalence of Cancer Treatments – 2015
Immuno-Oncology Diagnostics 2020 to 2024 Page | 13
Table of Tables
Table 1 List of Cancers by Mortality
Table 2 Lab Spending 2014 to 2024
Table 3 Overview of Innate and Adaptive Immunity
Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment
Table 5 FDA Approved Companion diagnostics in Cancer treatment
Table 6 Market Players by Type
Table 7 Five Factors Driving Growth
Table 8 Three Factors Limiting Growth
Table 9 Immuno-oncology Diagnostics Global Market by Country/Region
Table 10 Immuno-oncology Diagnostics Global Market by Type
Table 11 Checkpoint Assay Market by Country
Table 12 Cytokine Assay Market by Country
Table 13 Genome Germline Market by Country
Table 14 Genome Tumour Market by Country
Table 15 Tumour Micro Environment Market by Country
Table 16 Other Market by Country
Immuno-Oncology Diagnostics 2020 to 2024 Page | 14
Table of Figures
Figure 1 Cancer Death Rates – USA, CDC
Figure 2 Clinical Lab Spending 2014 to 2024
Figure 3 Helper T Cell Roles
Figure 4 Antibody Diagram
Figure 5 Macrophages attack a Cancer Cell
Figure 6 The Tumour Micro Environment
Figure 7 Comparing IO Diagnostic and Traditional Testing
Figure 8 Growth rates of IO DiagnosticTechnologies
Figure 9 Market Size by Country - Key Countries
Figure 10 Chart of Global Market by Assay Type Share
Figure 11 Growth Rates of Diagnostic Segments
Figure 12 IO Diagnostics Share Change by Type
Figure 13 Chart – Checkpoint Assay Market vs Total
Figure 14 Chart – Cytokine Assay Market vs Total
Figure 15 Chart – Genome Germline Market vs Total
Figure 16 Chart - Genome Tumour Market vs Total
Figure 17 Chart – Tumour Micro Environment Market vs Total
Figure 18 Chart – Other Market vs Total
Figure 19 FDA Cancer Drug Approvals by Year
Figure 20 Clinical Trials for Immunotherapy by Year
Figure 21 Pie Chart of Prevalence of Cancer Treatments

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook